Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIRTH: TACE-SBRT vs Y90 SIRT with Immunotherapy for HCC
NCT07293468Phase 3Recruiting
- Sponsor
- Tuen Mun Hospital
- Start
- Apr 2024
- Primary completion
- Mar 2034
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Tuen Mun Hospital. Started Apr 2024; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07293468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293468.